There is some evidence of IL6 and IL8 as prognostic biomarkers of survival in CRC patients and as predictive markers for response to bevacizumab treatment in renal cell carcinoma [45–47]. Here, IL6 is linked to hereditary clear cell renal cell carcinoma.